SEO URLwww.firestrike.ai/deals/ventyx-biosciences-lilly-acquisition-2026-8
acquisitionAnnounced · Jan 28, 2026PharmaceuticalsSource · CredibleArticle · Factual
Lilly acquires Ventyx Biosciences
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$1.2B
Target
Ventyx Biosciences
NASDAQ: VTYX · San Diego, California
Acquirer
Lilly
Full Acquisition
Status
Pending
Lilly agreed to acquire Ventyx Biosciences. Reported deal value: $1.2B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-28. Figures and status may change as filings and press coverage update.
By bringing Ventyx lead assets, VTX3232 and VTX2735, under its wing, Eli Lilly is positioning itself to address 'residual inflammation'—a critical health factor that remains even after successful treatment for obesity or cardiovascular disease
Deal timeline
Announced
Jan 28, 2026 · markets.financialcontent.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $1.2B. Figures and status may change as sources update.
Sources: markets.financialcontent.com · Primary article · FireStrike proprietary index